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ABSTRACT 
Endovascular treatment of intracranial aneurysms with intracranial stents was 
proven to be clinically safe and effective, but is still associated with a risk of 
thromboembolic complications. Stent thrombosis could be a sever complication 
associated with specific stent surface coatings and designs. Standardized in vitro tests 
for investigation of thrombogenicity induced by different nanomaterials were used 
as the basic method in carrying out the present study. Therefore, the aim of this study 
was to evaluate the thrombogenicity of three different nanomaterials (ZnO, TiO2 si 
Fe3O4) possible used as surface coating for intracranial stents. This study is based on 
a procedure for in vitro analyses of plasma coagulation time. To measure the plasma 
coagulation time, platelet-poor plasma from human whole blood was in vitro 
exposed to nanoparticles and analysed in prothrombin (PT) and activated partial 
thromboplastin (APTT). 
 
INTRODUCTION 
A variety of intracranial stents are used in permanent blood contact. 
Thrombogenicity is the property of a material to induce a thrombus 
formation, which may result in partial or complete blood vessel 
occlusion. Thus, thrombogenicity of intracranial stent may have 
important implication in the long-term outcome of neurosurgical 
patients that may lead to a life-threatening condition such as stroke. 
Stent / blood contact surface activity has been a widely subject 
discussed and reported and, notwithstanding the clinical significance of 
this phenomenon is still controversial.  
Moreover, the surface coatings of these implants that are in 
permanent contact with blood are often subjected to tests on 
coagulation in order to use the least thrombogenic materials. Activated 
partial thromboplastin time (aPTT), prothrombin time (PT) and the 
international normalized ratio (INR) are indicated as the techniques of 
choice used to help detect and diagnose a bleeding disorder or 
excessive clotting disorder. In our study, an in vitro model was 
established, which allows investigation of neurovascular stents with 
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regard to thrombogenicity and coagulation 
activation. The preliminary study was designed to 
compare these 3 methods to address the 
coagulation property of three biomaterials (ZnO, 
TiO2 si Fe3O4) with emphasis on the sensitivity and 
reproducibility of the test. These three biomaterials 
prepared in the form of nanoparticles were 
evaluated for their coagulation profile during 
incubation in human plasma. The study presents a 
revised version of these methods to include updated 
details on sample preparation of nanoparticles, 
selection of nanoparticle concentration for in vitro 
study, and updated details on test controls [4,5,6]. 
 
MATERIALS AND METHODS 
Platelet rich plasma (PRP) is obtained from fresh 
human blood derivative incubated with 
nanoparticles for 15 minutes at 37 ° C. This probe is 
subsequently analysed by evaluating the plasma 
coagulation time and how the nanoparticles affect 
this part of the haemostasis control system.  
 
The materials listed below are required for 
coagulation tests for the study of nanoparticles (Fig. 
1): 
1. Vacuum test tubes for coagulation testing; 
2. 12% sodium citrate. 
3. Thermostat bath; 
4. Special centrifuge with tubes test stand; 
5. Fresh human blood completely anti-coagulated 
with sodium citrate and obtained from at least 
three healthy donors known to be out of any anti-
inflammatory and antihistamine drug, blood 
thinning agents and birth control pills; 
6. APTT and PT / INR test cards for Abrazo Cascade 
equipment; 
7. Coagulation tester analyzer Abrazo Cascade 
System from Helena Laboratories; 
8. Nanoparticle sample for analysis. 
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Figure 1: A- aPTT tester card; B- PT / INR tester card; C- Abrazo 
Cascade Coagulation Test Equipment; D- Centrifuge; E- 
Vacuum test tubes with citrate; F- Thermostatic bath. 
 
PREPARATION OF THE STUDY SAMPLES 
The concentrations used in these assays are based 
on an estimated plasma concentration in a medium-
sized human patient at the desired therapeutic dose. 
In our study, we refer to this concentration as the 
theoretical concentration of plasma. The hypotheses 
and considerations for estimating theoretical plasma 
concentration have been reviewed in the literature 
[4] and are summarized below. 
For the calculation of nanoparticle concentration, 
we used in vitro test reports in mice. 
If the mouse dose used is approximately 123 mg / Kg 
in this example the human dose can be calculated as 
follows: 
 
 
 
It is known that blood volume accounts for about 8% 
of body weight (for example, an adult of 70 kg has 
about 5.6 L (8% of 70) blood. This allows an extremely 
crude estimate of maximum blood concentration. 
 
 
 
Each test evaluates a nanoparticle formulation of 
three different materials at preset concentrations. 
When the predicted therapeutic concentration is not 
known, the highest final concentration is 1 mg per 
ml.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: A- Blood collection; B- Centrifuge with multiple cartridges; C- Vacutainer tubes with centrifuged plasma.
 
PLASMA PREPARATION  
When the blood collection procedure is started the 
first 10 ml of blood must be discarded [fig.2] due to 
necessity to prevent the activation of cells and 
plasma biochemical cascades by the venous 
puncture procedure. Exposure and storage of blood 
or plasma at extreme temperatures (<20 C or> 37 C) 
can affect the quality of test results and should be  
 
avoided. Two types of plasma can be obtained to 
perform this experiment: platelet rich plasma (PRP), 
platelet poor plasma (PPP). Plasma from individual 
donors can be analyzed separately or collected 
together. The combined plasma is prepared by 
mixing plasma from at least two individual donors. 
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NORMAL TEST PLASMA PREPARATION  
Fresh whole blood must be used within 1 hour after 
collection. The blood is then centrifuged for 10 min 
at 3000 g at 20–22 C and plasma is collected from at 
least two donors. The combined plasma is stable for 
8 hours at room temperature. The assay can also be 
performed in plasma from individual donors, when 
needed for mechanical tracking experiments. Two 
duplicates (four total samples) of plasma test are 
analyzed in each of the coagulation tests. A duplicate 
is performed prior to analyzing the nanoparticle 
samples and the second duplicate at the end of each 
run to verify that plasma functionality is not affected 
throughout the experiment. 
 
NANOPARTICLE-TREATED TEST PLASMA PREPARATION  
In a micro-tube, 0.125 mg of nanoparticles and 1 ml 
of plasma are combined. Mix well on a shaker and 
incubate for 30 min at 37 ° C. Three test tubes are 
prepared for each test sample (ie, when each 
nanoparticle is tested at four concentrations, one 
needs three test tubes for each concentration for a 
total of 12 test tubes per nanoparticle test). 
 
PLASMA COAGULATION TESTS (Fig. 3) 
1. Prepare the Cascade Abrazo equipment as 
described in the manufacturer's manual. 
2. Preheat all tubes to 37 C. 
3. Configure the instrument test parameters for 
each of the two tests (aPTT and PT / INR). 
4. Add to the micro-tubes with pre-loaded 
nanoparticles 1 ml of plasma. 
5. Stir micro-tubes for 5 minutes. 
6. Scan each specific tester card (aPTT and INR / 
PT) before testing; 
7. Insert the test card into the Cascade Abrazo 
device; 
8. Allow the instrument to warm up before use. 
9. Extract the test solution with the micropipette. 
10. When the test timer starts, transfer the solution 
to the test card's geode by pressing the PIP 
button to activate the pipette. 
11.  When the time is up, the device will beep and 
the recording of coagulation time will remain 
displayed on the screen until further testing 
begins. 
12. The average of the three values must be 
calculated for each control or test. 
13. The average for each control and test sample 
should be between 25%. 
14. If two duplicates of the same study sample 
showed different results more than 5%, this 
sample was reanalysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Schematic  
diagram of coagulation 
time measurement. 
 
Donors 
Fresh 
blood 
Plas
ma 
Control samples with 
nanoparticles 
Test 
settings 
Data recording and 
analysis 
Card scan Card insertion 
Add test 
solution 
 408 A. Chiriac, Georgiana Ion, G. Stan et al. 
RESULTS 
The results shown in this study indicate that ZnO 
nanoparticles administered in the blood vessels can 
adsorb the coagulation factors in a specific form to 
the surface functional group, without activating 
these factors and that the adsorbed coagulation 
factors are not functional. Also, ZnO nanoparticles 
delayed the coagulation time with the size or surface 
functional group specificity, because all types of ZnO 
nanoparticles adsorbed the coagulation factors of 
the common pathway, some types of nanoparticles 
adsorbing more factors than others. The 
thrombogenicity study of TiO2 and Fe3O4 
nanoparticles suggests that nanoparticles should be 
an effective agent in prolonging the blood clotting 
time, thus exerting an anti-coagulant effect, thus 
improving the hemocompatibility of the coating. The 
ability of TiO2 and Fe3O4 nanoparticles to regulate 
platelet adhesion and plasma coagulation was thus 
demonstrated in vitro. 
 
 
 
 
 
DISCUSSIONS 
Treatment of neurosurgical patients with 
functionalized coating surfaces stents continues to 
evolve with the current emergence of nanoparticle 
functionalization technology that offers a 
combination of pharmacological and mechanical 
approaches to prevent thrombosis and arterial 
restenosis. Despite the promising short term and 
mid-term outcomes of surface coated stents, there 
are serious concerns about adverse clinical effects of 
late stent thrombosis. Certain nanoparticles 
intended for drug delivery application are designed 
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to reduce the effect of thrombogenicity of an 
intracranial stent in the bloodstream for a prolonged 
coagulation time in the circulatory system. Thus, a 
larger therapeutic window is offered until systemic 
anti-aggregation is administered. Studies evaluating 
nanoparticles effects on plasma coagulation time 
and their tendency to initiate vascular thrombosis 
are useful to assess nanoparticle thrombogenicity 
[1,2,3].  
A number of nanotechnology approaches have 
been borrowed and applied in stent technology. 
Stents with biofunctionalized surfaces with 
nanoparticles with high stability and carrier capacity, 
able to reduce the interaction with blood 
components and to incorporate substances as 
carriers for bioactive factors and drugs have been 
manufactured. There are already implants in the 
form of drug-eluting or biodegradable stents that 
induce healing reactions by triggering the body's 
natural processes [2,3]. 
At present, there is not much data on the 
thrombogenicity of stent materials dictated by nano-
scale observations. Because thrombogenicity is a 
multiparametric process, our study tests the 
hypothesis of the influence of surface 
nanotopography on platelet activation, in order to 
produce nano-coatings with less thrombogenic stent 
by adapting their surface properties. It is in fact 
intended to implement a real-time study of platelet 
response to biomaterials to improve 
hemocompatibility. 
The primary phenomenon of blood-material 
interaction was the rapid and selective adsorption of 
proteins through a three-step process represented 
by the transport to the interface, the adsorption 
reaction and the conformational rearrangement. 
Thus, the engineering of the surface properties 
(physical and chemical characteristics) of the 
implants aims to reduce the adsorption of proteins 
and cellular interactions resulting in the 
improvement of implant biocompatibility. 
Platelets are the main cells present in the blood 
that play the most important role in blood-material 
interactions. The adhesion of platelets to a surface is 
conditioned by two independent mechanisms. These 
are the transport of platelets to the surface, which 
depends on the flow conditions and the reaction of 
platelets with the surface, which depends on the 
nature of the surface and the adsorbed proteins. 
In this paper, we want to verify the influence of 
nanotopography and surface characteristics on the 
thrombogenicity of different possible types of nano-
coatings (ZnO, TiO2 and Fe3O4). Thus, the results 
obtained by us are in line with previous 
hemocompatibility studies in the literature regarding 
the influence of these nanoparticles on coagulation. 
These lead us to the conclusion that 
nanotopography and surface roughness of 
biomaterials influence their biological behaviour. 
The studies within our project will be continued by 
thrombogenicity analyses on nanoparticle-coated 
metal bands. 
 
This study about thrombogenicity induced by the 
nanoparticle is the subject of the grant: "New 
diagnostic and treatment methodologies: current 
challenges and technological solutions based on 
nanoparticles and biomaterials", that won the 2017 
complex projects completed in consortia CDI, grant 
number: PN-III-P1-1.2-PCCDI-2017-0062, funded by 
CNCS – UEFISCDI Romania. 
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